BRIEF—ICER to assess treatments for acute migraine

The US cost-effectiveness watchdog the Institute for Clinical and Economic Review (ICER) announced on Friday that it plans to assess the comparative clinical effectiveness and value of treatments for acute migraine.

These include: two oral CGRP receptor antagonists, rimegepant (from Biohaven Pharmaceutical) and ubrogepant (from Allergan); and a 5-HT1f agonist lasmiditan (from Eli Lilly).

All three of these agents are under Food and Drug Administration review with an anticipated decision in the final quarter of 2019.

The report will be reviewed during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council in January 2020.